Whether pregnant women presenting for the influenza A (H1N1) vaccination can have the mercury-free cevlapan vaccine.

The Committee for Medicinal Products for Human Use (CHMP) has given clear recommendation that both Celvapan and Pandemrix vaccines are safe for use in pregnant women at any stage of pregnancy. Both vaccines have been licensed for use in pregnant women by the European Commission and the European Medicines agency (EMEA).
The Joint Committee on Vaccination and Immunisation (JCVI) recommend that pregnant women should be given Pandemrix as it provides adequate levels of antibodies following administration of one dose, thereby conferring more rapid protection than Celvapan which requires two doses a minimum of three weeks apart.
Supplies of the Celvapan vaccine are limited therefore these are being reserved primarily for at-risk people with severe allergic reaction to egg products. Pandemrix is manufactured in hens eggs therefore is unsuitable for people with egg allergies, Celvapan does not contain egg products therefore is suitable for people with egg allergies.